DLBCL – Impact of Bridging therapies in Patients with Diffuse Large B-cell Lymphoma After 3 or More Lines of Treatment

The DESCAR-T registry was set up at the request of the health authorities to improve our knowledge of CAR T-cell therapies marketed in France to treat patients diagnosed with hematological malignancies. The objective of this registry is to collect data on the efficacy as well as on short- and long-term tolerance of these therapies in real-life setting.

Thanks to the data collected, the registry makes it possible to carry out projects to answer specific research questions. One of these projects is looking at the impact of bridge (waiting therapy) in CAR-T patients diagnosed with diffuse large B-cell lymphoma (DLBCL) after at least two previous lines of cancer treatment.

Why is this study being implemented?

Diffuse Large B-Cell Lymphoma is the most common type of non-Hodgkin lymphoma. Current treatments can cure the majority of patients. However, these treatments are not sufficiently effective for some patients. Either the disease progress despite the treatment (it is then considered “refractory”), or it relapses after a period of remission.

CAR T-cells are innovative therapies that have been offered for more than five years to some patients with relapsed or refractory DLBCL after at least two lines of treatment. Depending on the patient’s profile (e.g. their age) and disease (e.g. how quickly it progresses), other treatments may also be offered to patients. Before the injection of CAR-T, the patient is often given a waiting treatment called “bridge”, but the impact of bridge treatments on the effectiveness of response to CAR-T is still very little described. This project aims to provide the medical and scientific community with original elements of knowledge concerning the prognostic impact of bridge for CAR-T cell treatments in 3rd line of treatment or higher in patients with DLBCL.

What are the objectives of the study?

The study aims to describe the impact of bridge treatment in real life in patients with DLBCL who are offered CAR-T cells from the 3rd line of treatment.

How will the study be carried out?

This project is led by Dr. Guillaume Manson of the Rennes University Hospital and Dr. Rémy Dulery of the Saint Antoine Hospital of the Assistance Publique des Hôpitaux de Paris.

The study will be based on the analysis of data from the DESCAR-T registry. The analyses will be carried out by the LYSARC team. The report of this study will be sent to the project leaders, who will only receive descriptive results without individual data. No link can be established between the data contained in the report and the patients whose data is collected in DESCAR-T.

Analyses for this study began in February 2024 and the results are expected to be reported in a scientific and medical research journal in 2025.

FOR PATIENTS WHO HAVE BEEN OFFERED CAR-T THERAPY IN FRANCE

What does this project mean for you?

This project concerns patients included in the DESCAR-T registry, diagnosed with Diffuse Large B-Cell Lymphoma, for whom CAR T-cell therapy has been considered (outside clinical trials) in France after two other lines of treatment for this disease.

If you are in this situation and agree for your data to be used for this project, this has no direct implications for you.

What should you do about this study?

  • If you would like more information about the processing of your data in the context of DESCAR-T and this project,

Or

  • if you wish to exercise your rights regarding your data (access and rectification, limitation of their use),

⇒ inform the doctor at your hospital or centre of care for CAR T-cell therapy, who will contact LYSARC while maintaining your anonymity. You can also notify your decision by email at: dpo@lysarc.org.

 

  • Otherwise, you don’t have to do anything.

You can find more information about your rights in relation to your data “I am participating or have participated in a trial“.